PLUS THERAPEUTICS, Inc. Series S Warrant
PSTVZ
PSTVZ was delisted on the 26th of May, 2020.
5 hedge funds and large institutions have $4K invested in PLUS THERAPEUTICS, Inc. Series S Warrant in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
33% more capital invested
Capital invested by funds: $3K → $4K (+$1K)
17% less funds holding
Funds holding: 6 → 5 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UB
UMB Bank
Kansas City,
Missouri
|
+$227 |
Top Sellers
PSTVZ Hedge Fund Activity: Q1 2020 in Review
5 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in PLUS THERAPEUTICS, Inc. Series S Warrant (PSTVZ) for Q1 2020, worth a combined $4K — up 33% from $3K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PSTVZ and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was UMB Bank, adding an estimated $227.
- 5 institutional investors held PLUS THERAPEUTICS, Inc. Series S Warrant (PSTVZ) as of Q1 2020, down from 6 in Q4 2019.
- Funds reported $4K of PLUS THERAPEUTICS, Inc. Series S Warrant stock for Q1 2020, up 33% quarter-over-quarter.
- 0 funds opened new PLUS THERAPEUTICS, Inc. Series S Warrant positions in Q1 2020 and 1 closed out, a net change of -1 holder.
- The largest PLUS THERAPEUTICS, Inc. Series S Warrant buyer in Q1 2020 was UMB Bank, an estimated $227 added.
Based on aggregated 13F filings for Q1 2020.